# A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis

> **NCT05279131** · PHASE3 · COMPLETED · sponsor: **Almirall, S.A.** · enrollment: 105 (actual)

## Conditions studied

- Keratosis, Actinic

## Interventions

- **DRUG:** Tirbanibulin ointment 1%

## Key facts

- **NCT ID:** NCT05279131
- **Lead sponsor:** Almirall, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-28
- **Primary completion:** 2022-12-28
- **Final completion:** 2022-12-28
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2024-01-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279131

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279131, "A Study to Evaluate the Safety and Tolerability of Tirbanibulin Ointment 1% in Adult Participants With Actinic Keratosis". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT05279131. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*